BioWorld

Aug. 13, 2003

Lilly Drops Out Of One Program With Emisphere, Stays In Another

Emisphere Technologies Inc. lost a partner for one oral hormone replacement therapy but will continue to work in tandem on another oral hormone program. (BioWorld Today) Read More

FDA Rule That Limits Patent Stacking Set To Go Into Effect

Missing Out On Sunlight, Dietary Calcium, Vitamin D, Some North American Infants Getting Rickets

QLT Raises $150M In Notes Sale, Plans $50M Buyback Of Stock

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 26, 2026.

Brain-computer interfaces are here but long road ahead

BioWorld

The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...

Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

ENCALS 2026: From genetics to advancing strategies against ALS

BioWorld Science

Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...

Next wave of BCI firms builds on pioneers to tackle challenges

BioWorld

With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...

Boehringer Ingelheim identifies new mGlu3 receptor agonists

BioWorld Science

Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...